August 23, 2019
Pfizer Japan said on August 22 that its biosimilar version of the major cancer drug Herceptin (trastuzumab) is now available with the exact same indications and dosing schedules as Chugai Pharmaceutical’s originator product. The biosimilar, Trastuzumab BS for IV Infusion...read more